DOP64: Discovery of highly selective small molecule oral inhibitors of integrin α4β7 for the treatment of Inflammatory Bowel DiseasesECCO'20 Vienna 2020
DOP67: CKD-506, a selective histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis through regulation of NF-kB and AP-1 signaling pathwayECCO'20 Vienna 2020
DOP69: Tofacitinib in Ulcerative Colitis: Early ‘real world’ experience from four United Kingdom tertiary centresECCO'20 Vienna 2020
DOP70: High dimensional analysis reveals a novel signature for IL-17 producing CD8 T cells in Inflammatory Bowel DiseaseECCO'20 Vienna 2020
DOP71: Efficacy, safety, and tolerability of ustekinumab in pediatric patients with moderately to severely active Crohn’s Disease: Results from, UniStar, a phase 1 studyECCO'20 Vienna 2020
DOP72: Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of Ulcerative Colitis: The open-label, multicentre, Phase 2a TUSCANY studyECCO'20 Vienna 2020
DOP76: Corticosteroid sparing effects of ustekinumab therapy for Ulcerative Colitis through 2 years: UNIFI long-term extensionECCO'20 Vienna 2020
DOP78: Intestinal surgery rates in Ulcerative Colitis and Crohn’s Disease in the era of biologics – A Danish Nationwide Register Study from 2003-2016ECCO'20 Vienna 2020
DOP79: Dose escalation of upadacitinib in Crohn’s Disease patients with inadequate response: Data from the randomised CELEST studyECCO'20 Vienna 2020
DOP80: Effectiveness of ustekinumab and vedolizumab in patients with Crohn’s Disease refractory to anti-tumor necrosis factor: A multi-center comparative studyECCO'20 Vienna 2020
DOP82: Macrophages in Crohn’s Disease mesentery are predominantly inflammatory and produce calprotectinECCO'20 Vienna 2020
DOP84: Crohn’s Disease modifies the DNA methylome of human adipose-stem cells, which is only partially re-established in remissionECCO'20 Vienna 2020